Paesi Bassi - olandese - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

pharmachemie b.v. - calciumcarbonaat (e 170) samenstelling overeenkomend met ; calcium (ca2+) - bruistablet - aspartaam (e 951) ; citroenzuur 0-water (e 330) ; dimeticon (e 900) ; lactose 1-water ; lemon flavour 00299 ; methylcellulose (e 461) ; polyethyleenglycol (e 1521) ; povidon (e 1201) ; saccharoide natrium x-water (e 954) ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200), - calcium carbonate

Paesi Bassi - olandese - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. swensweg 5 2031 ga haarlem - calciumcarbonaat (e 170) 2778 mg/stuk samenstelling overeenkomend met ; calcium (ca2+) 1000 mg/stuk ; cholecalciferol 880 ie/stuk - kauwtablet - arabische gom (e 414) ; aspartaam (e 951) ; magnesiumstearaat (e 470b) ; maltodextrine ; mannitol (d-) (e 421) ; natriumascorbaat (e 301) ; saccharose ; siliciumdioxide (e 551) ; sinaasappelsmaakstof ; tocoferol, dl-alfa (e 307) ; triglyceriden middellange keten ; zetmeel, gemodificeerd (modificatie onbekend) (e 1440), arabische gom (e 414) ; aspartaam (e 951) ; magnesiumstearaat (e 470b) ; maltodextrine ; mannitol (d-) (e 421) ; natriumascorbaat (e 301) ; saccharose ; siliciumdioxide (e 551) ; sinaasappelsmaakstof ; tocoferol, dl-alfa (e 307) ; triglyceriden middellange keten ; zetmeel, gemodificeerd (modificatie onbekend), - calcium, combinations with vitamin d and/or other drugs

Paesi Bassi - olandese - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. swensweg 5 2031 ga haarlem - calciumcarbonaat (e 170) 1389 mg/stuk samenstelling overeenkomend met ; calcium (ca2+) 500 mg/stuk ; cholecalciferol 440 ie/stuk - kauwtablet - arabische gom (e 414) ; aspartaam (e 951) ; magnesiumstearaat (e 470b) ; maltodextrine ; mannitol (d-) (e 421) ; natriumascorbaat (e 301) ; saccharose ; siliciumdioxide (e 551) ; sinaasappelsmaakstof ; tocoferol, dl-alfa (e 307) ; triglyceriden middellange keten ; zetmeel, gemodificeerd (modificatie onbekend) (e 1440), arabische gom (e 414) ; aspartaam (e 951) ; magnesiumstearaat (e 470b) ; maltodextrine ; mannitol (d-) (e 421) ; natriumascorbaat (e 301) ; saccharose ; siliciumdioxide (e 551) ; sinaasappelsmaakstof ; tocoferol, dl-alfa (e 307) ; triglyceriden middellange keten ; zetmeel, gemodificeerd (modificatie onbekend), - calcium, combinations with vitamin d and/or other drugs

Francia - francese - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

teva sante - calcium élément - comprimé - 500,00 mg - composition pour un comprimé > calcium élément : 500,00 mg . sous forme de : carbonate de calcium > cholécalciférol : 400 ui . sous forme de : concentrat de cholécalciférol, forme pulvérulente 4,00 mg - calcium en association avec d'autres substances

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate.  animal reproduction studies have not been conducted with calcium acetate capsules, and there are no adequate and well controlled studies of calcium acetate capsules use in pregnant women.  patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] .  maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism.  calcium acetate capsules treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium a

Stati Uniti - inglese - NLM (National Library of Medicine)

pharmin usa, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablet is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd).

Stati Uniti - inglese - NLM (National Library of Medicine)

atlantic biologicals corps - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see ]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. warnings and precautions (5.1) the effects of calcium acetate

Stati Uniti - inglese - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a

Stati Uniti - inglese - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown.

Stati Uniti - inglese - NLM (National Library of Medicine)

cipla usa inc., - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a